Table 1 Characteristics of the patients treated in WINTHER trial investigated with DDPP.

From: Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival

Study ID

Age

Sex

Cancer site

Prior lines

PFS months

DNA—list of molecular alterations (Foundation Medicine report)a

Drug_given

203

67

F

GI/NE

1

60.0+

No mutation

Everolimus

148

82

M

GI/NE

2

11.6

BCOR N1652fs*34; CDKN1B E126fs*1

Everolimus

6

64

F

UP

1

8.1

TSC1 splice site 913 + 1G > T; BRCA1 truncation, intron 11; CDKN2A/B loss; DNMT3A R882H; LRP1B loss

Everolimus

117

34

M

HN

2

1.9

TSC2 S1431L; TP53 G245S; BCOR K374fs*19; SMARCA4 R1135W

Everolimus

227

56

M

LS

4

1.7

STK11 F354L; STK11 F354L; TERT promoter —124C > T

Everolimus

90

74

M

HN

2

1.3

PIK3CA Q546R; EP300 D1154fs*30; NOTCH1 L1746fs*40

Everolimus

83

59

M

HN

4

8.8

MTOR L2209V; ETV6 trunc intron 5; CIC S333fs*36; MLL2 G3698 fs*51

Axitinib

223

65

F

HN

3

7.1

CCND1 T2861

Axitinib

259

53

F

HN

4

6.2

PDGFRA amp

Axitinib

25

65

M

HN

2

5.3

TP53 I195F; KDM6A L725fs*4; MSH6 K1358fs*2; NFE2L2 R18Q

Axitinib

88

56

M

Lung

1

2.9

DNMT3A R635P; KRAS G12C; TP53 Y220C; MLL2 T1246M

Axitinib

149

54

F

CRC

5

7.4

KRAS G12V; ARID1A SPLICE SITE 2733-1G > A

Trametinib

100

43

M

Lung

2

6.6

BRAF A598_T599insT; IDH1 R132C

Trametinib

118

78

F

Lung

3

3.1

KRAS G12C; CDKN2A/B loss; TP53 V157F, Y220 fs*27; MUTYH G382D

Trametinib

156

71

F

Lung

2

14.3

EGFR E746_A750del, T790M; CDKN2A/B loss; CTNNB1 S33F; MYC amplification; SMAD4 P186fs*6; STAG2 splice site 1535-12_1630del108

Afatinib + cetuximab

235

60

F

Lung

1

11.3

ERBB2 A775_G776insYVMA

Afatinib

136

79

M

Lung

3

0.4

ERBB3 amp; MET splice site 3028 + 1G > A; STK11 Q100* ATM L2450fs*11; BRCA1 E23fs*17; CDK4 amp; CDKN2A/B loss; MDM2 amp; APC I1307K; KDM5C truncation; MAP3K1 S1475*

Afatinib

237

47

M

HN

6

19.3

CCND1 amp; FGFR2 amp; CDKN2A/B loss; FGF19 amp; FGF4 amp; BAP1 trunc exon 3; FGF3 amp; MAGI2 Q1077*; PBRM1 E1155fs*17

NCT01004224 BGJ398

247

67

M

Esophagus

2

1.6

FGFR2 amp; CDKN2A/B loss; TP53 W91*; ASXL1 splice site 472-2A > G

NCT02052778 TAS-120

228

38

M

CRC

5

0.7

FGFR1 amp; TP53 C176F; APC E1322*, R213*; SMAD4 loss; SOX9 V163fs*21

NCT02052778 TAS-120

183

66

M

CRC

2

61.0+

RBB3; V104M; MAP2K1; E203K; CDKN2A/B loss; FBXW7 R465C; PIK3CA E39K; PIK3R1 R348*, R639*; PTEN R233*, splice site 801 + 2T > G; TP53 R158H, R273H; APC R1450*, R499*; ARID1A P1115fs*46, Q1306fs*17; ATRX Q2422*; CDH1 D433N; EP300 R2263*; FAM123B R631*; FAT1 A4305V; FLCN H429fs*39; MSH6 L1330fs*12, S279fs*12

Pembrolizumab

(TMB: 74.8)

(MSI: +)

294

57

M

HN

1

1.7

BRCA2 K3408*

Nivolumab

(TMB: 0)

(MSI: −)

270

76

F

CRC

3

0.9

FLT4 amp; FLT3 amp equivocal; BARD1 C53fs*5; MYC amp; PARK2 loss exons 3–5; TP53 R175H; APC T1556fs*3; BCL2L1 amp; CDK8 amp; ETV6 rearrangement intron 5; FAM123B R497*; GATA6 amp equivocal; KDM6A-Y215*; MUTYH-Y165C; NOTCH1 Q2123*

Atezolizumab

(TMB: 10.4)

(MSI: −)

  1. Foundation Medicinea10; ID 203, PFS 60+ and OS60+ are censored values, updated from the WINTHER trial Supplemental Table 3, Abbreviations: GI gastrointestinal, NE neuroendocrine, HN head and neck, UP unknown primary, LS liposarcoma, TMB tumor mutation burden, MSI microsatellite instability, amp amplification, del deletion, trunc truncation.
Back to article page